RxDoctor Payments Data

John Adams, DO

Interventional Pain Medicine · Pensacola, FLNPI 1639109739

Payments from drug & device makers

$6,397in general payments, 2019–2025

Across 179 payments — averaging $35.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Nevro Corp.$585
  • Collegium Pharmaceutical, Inc.$458
  • Boston Scientific$372
  • Scilex Pharmaceuticals Inc.$358
  • Medtronic$358
  • plus $873 from 22 others

What the payments were for

  • Travel & lodging$1,26820%
  • Food & beverage$5,12280%
  • Education$60%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,397 in reported general payments places this provider in the 55th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$393,304
Medicare patients
437
Services billed
5,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl61$49,921
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,860$48,539
Buprenorphine186$41,765
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,152$38,354
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl186$18,708
ZtlidoLidocaine27$17,465
Xtampza ErOxycodone Myristate37$15,873
LyricaPregabalin12$9,033
Fentanyl54$5,515
Tramadol Hcl575$5,376
Pregabalin255$4,426
Tramadol Hcl ErTramadol Hcl66$3,852
Oxycodone Hcl264$3,238
Buprenorphine Hcl66$2,751
Lidocaine22$2,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$458$65,79398 claims
Scilex Pharmaceuticals Inc.Ztlido$358$17,46527 claims
PfizerLyrica$48$9,03312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →